Hematology Oncology and Stem Cell Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Letter to the editor concerning “Single-institution experience of performing bloodless transplant in Jehovah’s Witness patients” by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol oncol stem cell ther 2019;12(1):44–9.)
Publication date: Available online 11 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jennifer C. Zhao, Justin R. Arnall, Allison L. Martin, Saad Usmani, Shebli Atrash (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 31, 2019 Category: Cancer & Oncology Source Type: research

Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry.
ConclusionWhile radiation therapy might increase long-term toxicity in cHL, in our large data cohort, radiotherapy consolidation as part of the initial therapy for early stage disease provides superior survival at 10 years, especially in favorable risk cHL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 29, 2019 Category: Cancer & Oncology Source Type: research

High-Dose Intravenous Methotrexate in the Management of Breast Cancer with Leptomeningeal Disease: Case Series and Review of the Literature
Publication date: Available online 14 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jonathan T. Kapke, Robert J. Schneidewend, Zeeshan A. Jawa, Chiang-Ching Huang, Jennifer M. Connelly, Christopher R. Chitambar (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 15, 2019 Category: Cancer & Oncology Source Type: research

How a Population-based Analysis Compares to Clinical Trials in Early Stage Classical Hodgkin Lymphoma
ConclusionWhile radiation therapy might increase long-term toxicity in cHL, in our large data cohort, radiotherapy consolidation as part of the initial therapy for early stage disease provides superior survival at 10 years, especially in favorable risk cHL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 15, 2019 Category: Cancer & Oncology Source Type: research

Outcomes of High-Risk Acute Promyelocytic Leukemia patients Treated with Arsenic Trioxide (ATO)/All Trans Retinoic Acid (ATRA) Based Induction and Consolidation Without Maintenance Phase
We present a retrospective analysis of 10 patients that were treated for high risk APL based on the consolidation treatment phase of APL 0406 study without subsequent maintenance. With a median follow up of 38 months, all patients remain in remission. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 15, 2019 Category: Cancer & Oncology Source Type: research

Comparative Effectiveness of Busulfan/Cyclophosphamide versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
ConclusionWe confirmed that myeloablative Bu/Flu conditioning has comparable clinical and QOL outcomes to Bu/Cy. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2019 Category: Cancer & Oncology Source Type: research

The AUGMENT Study: Lenalidomide in Indolent Lymphoma … Balance the Imbalance!
Publication date: Available online 11 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Reyad Dada (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2019 Category: Cancer & Oncology Source Type: research

Letter to the Editor concerning “ Single-institution experience of performing bloodless transplant in Jehovah’s Witness patients” by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol Oncol Stem Cell Ther 2019;12(1):44–9.)
Publication date: Available online 11 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jennifer C. Zhao, Justin R. Arnall, Allison L. Martin, Saad Usmani, Shebli Atrash (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2019 Category: Cancer & Oncology Source Type: research

The Role of Recombinant Human Erythropoietin in Neonatal Anemia
ConclusionEPO therapy in conjunction with iron, vitamin E and folic acid, stimulated erythropoiesis and significantly reduced the need for blood transfusion in AOP and corrected late hypo-regenerative post hemolytic anemia. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2019 Category: Cancer & Oncology Source Type: research

Synchronous Multiple Myeloma and Gaucher Disease
Publication date: Available online 9 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jorge Monge, Amy Chadburn, Usama GergisAbstractPseudo-Gaucher cells can be found in multiple hematologic malignancies, hemoglobinopathies, infections, and multiple storage disorders upon bone marrow aspirate and biopsy; however, Gaucher disease (GD) should be ruled out, particularly when the cytoplasmic inclusions cannot be adequately characterized. It is well known that GD may be associated with monoclonal gammopathies; however, although enzyme replacement therapy (ERT) may result in an improvement in polyclonal ga...
Source: Hematology Oncology and Stem Cell Therapy - October 10, 2019 Category: Cancer & Oncology Source Type: research

Clinical Predictors of Delayed Engraftment in Autologous Hematopoietic Cell Transplant Recipients
ConclusionTransfusion dependence prior to AHCT, pre-AHCT platelet count, and CD34+ cell dose were the strongest predictors of delayed engraftment in patients undergoing AHCT. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 10, 2019 Category: Cancer & Oncology Source Type: research

The Effects of Granulocyte Colony-Stimulating Factors (G-CSFs) in Leucocytes
We present a case report of a 29-year-old woman where these laboratory findings are described. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 10, 2019 Category: Cancer & Oncology Source Type: research

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond
Publication date: Available online 20 August 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Marcelo C. Pasquini, Alok Srivastava, Syed Osman Ahmed, Mahmoud Aljurf, Yoshiko Atsuta, Carol Doleysh, Sebastian Galeano, Eliane Gluckman, Hildegard Greinix, Gregory Hale, Parameswaran Hari, Shahrukh K. Hashmi, Naynesh Kamani, Mary J. Laughlin, Dietger Niederwieser, Adriana Seber, Jeffrey Szer, John A. Snowden, Koen Van Biesen, Paula WatryAbstractHematopoietic cell transplantation (HCT) is a highly complex procedure that requires a dedicated multidisciplinary team to optimize its safety. In addition, institutions ma...
Source: Hematology Oncology and Stem Cell Therapy - August 21, 2019 Category: Cancer & Oncology Source Type: research

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): clinical, technical and socio-economic considerations
This report describes recommendations from the Worldwide Network for Blood and Marrow Transplantation (WBMT) for establishing HSCT programs with a specific focus on developing countries, and identifies challenges and opportunities for providing this specialized procedure in the resource constrained setting. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 21, 2019 Category: Cancer & Oncology Source Type: research

Autologous Stem Cell Transplantation may be Curative for Patients with Follicular Lymphoma with Early Therapy Failure without the need for Immunotherapy
ConclusionASCT may be a curative option for ETF in patients who respond to rescue chemotherapy, without the need for immunotherapy or other therapies, and should be considered as an early consolidation, especially in patients with difficult access to rituximab. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2019 Category: Cancer & Oncology Source Type: research